A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

Access to the obesity medications known as GLP-1 receptor agonists has been a consistent problem for patients because of ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

The announcement comes on the heels of a deal with the Trump administration to expand access to weight-loss drugs and reduce ...

After [losing out to Pfizer]( ...

“Weight loss can cause hair fall by telogen effluvium anyway, but GLP-1s now have been shown to cause hair fall themselves,” ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

The results were published in The New England Journal of Medicine as part of the OASIS 4 phase 3 trial. The findings show ...

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new ...

A Trump administration deal to slash prices on blockbuster weight-loss drugs such as Wegovy and Zepbound is expected to make ...